| Literature DB >> 22606024 |
Puchakayala Muralidhar Reddy1,2, Rondla Rohini1,2, Edulla Ravi Krishna1, Anren Hu3, Vadde Ravinder1.
Abstract
A novel family of tetraaza macrocyclic Cu(II) complexes [CuLX(2)] (where L = N(4) donor macrocyclic ligands) and (X = Cl(-), NO(3) (-)) have been synthesized and characterized by elemental analysis, magnetic moments, IR, EPR, mass, electronic spectra and thermal studies. The magnetic moments and electronic spectral studies suggest square planar geometry for [Cu(DBACDT)]Cl(2) and [Cu(DBACDT)](NO(3))(2) complexes and distorted octahedral geometry to the rest of the ten complexes. The biological activity of all these complexes against gram-positive and gram-negative bacteria was compared with the activity of existing commercial antibacterial compounds like Linezolid and Cefaclor. Six complexes out of twelve were found to be most potent against both gram-positive as well as gram-negative bacteria due to the presence of thio group in the coordinated ligands.Entities:
Keywords: antibacterial studies; copper(II) complexes; synthesis; tetraaza macrocycles
Mesh:
Substances:
Year: 2012 PMID: 22606024 PMCID: PMC3344260 DOI: 10.3390/ijms13044982
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Physical, analytical and electronic spectral data of macrocyclic Cu(II) complexes.
| Comp. No. | Cu(II) Compound/Molecular Formula | ΛM | μeff (B.M.) | λmax (cm−1) | Analyses (%) Found (Calculated) | |||
|---|---|---|---|---|---|---|---|---|
| C | H | N | Cu | |||||
| 1.1. | [Cu(HBOADO)Cl2] | 16.2 | 1.96 | 16008, 21226 | 42.38 (42.32) | 3.18 (3.16) | 22.04 (21.94) | 12.36 (12.44) |
| 1.2. | [Cu(TBACD)Cl2]·2H2O | 14.0 | 1.98 | 17348, 22801 | 41.33 (41.83) | 3.52 (3.51) | 16.23 (16.26) | 12.25 (12.30) |
| 1.3. | [Cu(OBACI)Cl2] | 13.5 | 1.96 | 17857, 21988 | 56.88 (56.86) | 5.57 (5.57) | 11.02 (11.05) | 12.56 (12.53) |
| 1.4. | [Cu(HBOADT)Cl2] | 12.4 | 1.94 | 17847, 21255 | 40.01 (39.82) | 2.84 (2.97) | 20.72 (20.64) | 11.55 (11.70) |
| 1.5. | [Cu(DBACDT)]Cl2 | 65.0 | 1.91 | 13065, 18181 | 44.42 (44.77) | 2.68 (2.50) | 11.72 (11.60) | 13.07 (13.16) |
| 1.6. | [Cu(TBAHD)Cl2]·2H2O | 16.5 | 1.92 | 17699, 22527 | 41.95 (41.82) | 3.50 (3.51) | 16.22 (16.26) | 12.24 (12.29) |
| 2.1. | [Cu(HBOADO)(NO3)2] | 15.3 | 1.93 | 16422, 21712 | 38.23 (38.34) | 3.02 (2.86) | 24.81 (24.84) | 11.34 (11.27) |
| 2.2. | [Cu(TBACD)(NO3)2] | 16.1 | 1.89 | 17758, 22954 | 40.42 (40.49) | 2.84 (2.64) | 21.10 (20.99) | 11.87 (11.90) |
| 2.3. | [Cu(OBACI)(NO3)2] | 14.8 | 1.94 | 18201, 22147 | 51.48 (51.47) | 5.05 (5.04) | 15.06 (15.01) | 11.38 (11.35) |
| 2.4. | [Cu(HBOADT)(NO3)2] | 12.9 | 1.86 | 18348, 21875 | 36.24 (36.27) | 2.68 (2.71) | 23.42 (23.50) | 10.72 (10.66) |
| 2.5. | [Cu(DBACDT)](NO3)2 | 68.3 | 1.89 | 13524, 18457 | 40.31 (40.34) | 2.16 (2.26) | 15.74 (15.68) | 11.91 (11.86) |
| 2.6. | [Cu(TBAHD)(NO3)2] | 15.4 | 1.93 | 17700, 22756 | 38.12 (38.20) | 2.54 (2.49) | 19.82 (19.80) | 11.34 (11.23) |
Infrared spectral data of macrocyclic Cu(II) complexes.
| Comp. No. | Cu(II) Compound | Selected IR Bands (cm−1) | |||
|---|---|---|---|---|---|
| υC=N | υNH | υCu–N | Anion Peaks | ||
| 1.1. | [Cu(HBOADO)Cl2] | 1578 | 3320 | 516 | 307 |
| 1.2. | [Cu(TBACD)Cl2]2·H2O | 1575 | 3326 | 518 | 304 |
| 1.3. | [Cu(OBACI)Cl2] | 1596 | - | 520 | 318 |
| 1.4. | [Cu(HBOADT)Cl2] | 1590 | 3324 | 524 | 302 |
| 1.5. | [Cu(DBACDT)]Cl2 | 1598 | - | 506 | - |
| 1.6. | [Cu(TBAHD)Cl2]2·H2O | 1585 | 3383 | 520 | 314 |
| 2.1. | [Cu(HBOADO)(NO3)2] | 1580 | 3318 | 510 | 235 |
| 2.2. | [Cu(TBACD)(NO3)2] | 1573 | 3325 | 515 | 230 |
| 2.3. | [Cu(OBACI)(NO3)2] | 1595 | - | 518 | 240 |
| 2.4. | [Cu(HBOADT)(NO3)2] | 1587 | 3326 | 520 | 230 |
| 2.5. | [Cu(DBACDT)](NO3)2 | 1595 | - | 505 | - |
| 2.6. | [Cu(TBAHD)(NO3)2] | 1580 | 3379 | 518 | 235 |
EPR spectral data of macrocyclic Cu(II) compounds.
| Comp. No. | Cu(II) Compound | g11 | g⊥ | |g|avg | G |
|---|---|---|---|---|---|
| 1.1. | [Cu(HBOADO)Cl2] | 2.119 | 2.024 | 2.055 | 4.958 |
| 1.2. | [Cu(TBACD)Cl2]·2H2O | 2.212 | 2.043 | 2.099 | 4.930 |
| 1.3. | [Cu(OBACI)Cl2] | 2.118 | 2.021 | 2.053 | 5.619 |
| 1.4. | [Cu(HBOADT)Cl2] | 2.219 | 2.039 | 2.099 | 5.615 |
| 1.5. | [Cu(DBACDT)]Cl2 | 2.220 | 2.046 | 2.104 | 4.782 |
| 1.6. | [Cu(TBAHD)Cl2]·2H2O | 2.171 | 2.029 | 2.076 | 5.896 |
| 2.1. | [Cu(HBOADO)(NO3)2] | 2.108 | 2.022 | 2.050 | 4.909 |
| 2.2. | [Cu(TBACD)(NO3)2] | 2.177 | 2.040 | 2.085 | 4.425 |
| 2.3. | [Cu(OBACI)(NO3)2] | 2.085 | 2.018 | 2.040 | 4.722 |
| 2.4. | [Cu(HBOADT)(NO3)2] | 2.165 | 2.030 | 2.075 | 5.500 |
| 2.5. | [Cu(DBACDT)](NO3)2 | 2.161 | 2.040 | 2.080 | 4.025 |
| 2.6. | [Cu(TBAHD)(NO3)2] | 2.110 | 2.019 | 2.049 | 5.789 |
Scheme 1Representative structures of copper complex.
Minimum inhibitory concentration (MIC) of Cu(II) macrocyclic complexes against test bacteria.
| Comp. No. | Macrocyclic Cu(II) Complexes | MIC (μg/mL) | ||||
|---|---|---|---|---|---|---|
| Sa | Bp | Bm | Pa | Se | ||
| 1.1. | [Cu(HBOADO)Cl2] | 8 | 6 | 10 | 16 | 12 |
| 1.2. | [Cu(TBACD)Cl2]·2H2O | 8 | 10 | 16 | 8 | 12 |
| 1.3. | [Cu(OBACI)Cl2] | 16 | 10 | 8 | 12 | 9 |
| 1.4. | [Cu(HBOADT)Cl2] | 2 | 4 | 4 | 16 | 2 |
| 1.5. | [Cu(DBACDT)]Cl2 | 2 | 8 | 4 | <16 | 1 |
| 1.6. | [Cu(TBAHD)Cl2]·2H2O | 4 | 4 | 2 | 16 | 2 |
| 2.1. | [Cu(HBOADO)(NO3)2] | 10 | <16 | 8 | >16 | 10 |
| 2.2. | [Cu(TBACD)(NO3)2] | 10 | 10 | 8 | 16 | 12 |
| 2.3. | [Cu(OBACI)(NO3)2] | 16 | 8 | 16 | >16 | >16 |
| 2.4. | [Cu(HBOADT)(NO3)2] | 2 | 2 | 4 | 16 | 1 |
| 2.5. | [Cu(DBACDT)](NO3)2 | 2 | 4 | 4 | <16 | 2 |
| 2.6. | [Cu(TBAHD)(NO3)2] | 4 | 2 | 4 | 16 | 2 |
| Linezolid | 4 | 4 | 4 | <16 | <16 | |
| Cefaclor | 2 | 8 | 8 | <16 | 2 | |
Sa: S. aeruginosa (ATCC-29213); Bp: B. pumilus (MTCC-1456); Bm: B. megaterium (MTCC-428); Pa: P. aeruginosa (ATCC-27853); Se: S. epidermidis (MTCC-2639).
Figure 1Comparison of MIC values (in μg/mL) of Cu(II) macrocyclic complexes and standard drugs against different bacteria.